Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2851

Sigma-Aldrich

Galunisertib

≥98% (HPLC)

Synonym(s):

2-(6-Methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole, 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide, 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide, LY 2157299, LY-2157299, LY2157299

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
€85.90
25 MG
€349.00

€85.90

Please contact Customer Service for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
€85.90
25 MG
€349.00

About This Item

Empirical Formula (Hill Notation):
C22H19N5O
CAS Number:
700874-72-2
Molecular Weight:
369.42
MDL number:
MFCD12923319
UNSPSC Code:
12352200
NACRES:
NA.77

€85.90

Please contact Customer Service for Availability
Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[n]21nc(c(c2CCC1)c4c5c(ncc4)ccc(c5)C(=O)N)c3nc(ccc3)C

InChI

1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)

InChI key

IVRXNBXKWIJUQB-UHFFFAOYSA-N

Biochem/physiol Actions

Galunisertib (LY2157299) is an orally active multikinase inhibitor (IC50 in nM = 80/ALK4, 170/TGFβR1, 210/TGβ?R2, 190/MINK (MAP4K6), 220/RIP2 (RIPK2), 260/CK1α, 280/MEKKK4, 310/GAK, 400/CK1ε, 470/ALK6 (BMPR1B), 500/B-raf, 510/TNIK) mostly cited for its ALK4 & TGFbeta (TGFβ) receptors (TGFβ-RI (ALK5) & TGFβ-RII) inhibitory activity and anticancer efficacy in vitro (0.1-10 μM) and in vivo (20-100 mg/kg p.o.; mice).
Orally active multikinase inhibitor best known for its ALK4, TGFbeta receptors TGFβ-RI (ALK5) & TGFβ-RII activity and anticancer efficacy in vitro and in vivo.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000438795
0000438794
0000438794
0000438795
0000427091

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Linlin Shi et al.
Theranostics, 9(14), 4115-4129 (2019-07-10)
Galunisertib (Gal) is a transforming growth factor (TGF-β) blockade which is being investigated as a potential tumor immunotherapy candidate drug in clinical trials. However, primary or acquired resistance is often found in the recruited cancer patients, which limits its clinical
Armin Maier et al.
Cellular oncology (Dordrecht), 38(2), 131-144 (2015-01-13)
The transforming growth factor-beta (TGF-β) signaling pathway is known to play a critical role in promoting tumor growth. Consequently, blocking this pathway has been found to inhibit tumor growth. In order to achieve an optimal anti-tumor effect, however, it remains
Mariafrancesca Cascione et al.
International journal of molecular sciences, 20(1) (2019-01-02)
The epithelial mesenchymal transition (EMT) is a physiological multistep process involving epithelial cells acquiring a mesenchymal-like phenotype. It is widely demonstrated that EMT is linked to tumor progression and metastasis. The transforming growth factor (TGF)-β pathways have been widely investigated
Wan He et al.
Cancer cell international, 19, 160-160 (2019-06-15)
Our previous studies revealed that Jagged 2 (JAG2) is involved in the regulation of migration and invasion of colon cancer cells without affecting cell proliferation. This study further explored the specific mechanism by which JAG2 promotes migration and invasion of
Wenlong Li et al.
International journal of cancer, 146(6), 1631-1642 (2019-07-16)
Galunisertib (LY2157299), a promising small-molecule inhibitor of the transforming growth factor-beta (TGF-β) receptor, is currently in mono- and combination therapy trials for various cancers including glioblastoma, hepatocellular carcinoma and breast cancer. Using genetically modified mouse models, we investigated the roles
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service